EXACT Sciences — Q1 2024 Earnings Presentation
16 slides from EXACT Sciences's earnings presentation, May 8, 2024
Slide 1: First-quarter 2024 earnings call
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. First-quarter 2024 earnings call May 8, 2024 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Exact Sciences is a leader in advanced cancer diagnostics
Exact Sciences is a leader in advanced cancer diagnostics OUR TEAM OUR FLAGSHIP TESTS Q1 RESULTS 500 1M+ Total revenue of $638M and adjusted EBITDA of $39M R&D team members test results in 1Q24 1,300 Maintained full-year 2024 revenue and adj. EBITDA guidance person commercial team 120 Published Colo
Slide 4: Core revenue grew 6% in 1Q24
Core revenue grew 6% in 1Q24 Core revenue Screening revenue Precision Oncology core revenue $634M $597M +6% $475M $443M +7% $153M $159M +4% 1Q23 1Q24 1Q23 1Q24 1Q23 1Q24 Please refer to our first-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and rec
Slide 5: Well-positioned to achieve 2024 guidance, which has been maintained
Well-positioned to achieve 2024 guidance, which has been maintained Prior guidance May 8 update ∆ at midpoint Total revenue $2.810 - 2.850B $2.810 - 2.850B - Screening $2.155 - 2.175B $2.155 - 2.175B - Precision Oncology $655 - 675M $655 - 675M - Adj. EBITDA $325 - 350M $325 - 350M - CapEx ~$150M ~$
Slide 6: The strategic importance of Cologuard in colon cancer screening is growing
The strategic importance of Cologuard in colon cancer screening is growing Increasing awareness and Cologuard adoption through new, targeted marketing experiences Expanding sales reach and frequency to engage 60M unscreened Americans Helping healthcare providers, health systems, and payors improve s
Slide 7: Expanding Oncotype DX impact globally, creating new growth opportunities
Expanding Oncotype DX impact globally, creating new growth opportunities Sustainable, double-digit growth internationally Strong double-digit international growth 20%+ High margins, steady cash flow Future growth opportunities across portfolio increase in international ordering providers y/y Source:
Slide 8: Leveraging our platform by bringing new tests to patients and healthcare providers
Leveraging our platform by bringing new tests to patients and healthcare providers Strong double-digit international growth solid tumor molecular colorectal cancer screening residual disease PRECISION SCREENING ONCOLOGY colorectal cancer screening therapy selection (blood) Tests are in development a
Slide 9: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment
Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 9
Slide 10: EXACT SCIENCES
EXACT SCIENCES 10
Slide 11: Condensed Consolidated Statements of Operations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended March 31, 2024 2023 Revenue $ 637,524 $ 602,450 Operating expenses Cost of sales (exclusive of amortization of acquired
Slide 12: Condensed Consolidated Balance Sheets
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, March 31, 2024 2023 Assets Cash and cash equivalents $ 347,487 $ 605,378 Marketable securities 304,606 172,266 Accounts receivable, net 240,584 203,623 Invent
Slide 13: Reconciliation of Core Revenue
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended March 31, 2024 2023 % Change Screening $ 474,798 $ 443,195 7 % Precision Oncology 162,726 155,432 5 % COVID-19 Testing — 3,823 (100) % Total $ 637,524 $ 6
Slide 14: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended March 31, 2024 2023 Revenue $ 637,524 $ 602,450 Cost of sales (exclusive of amortization of acquired intangible assets) 170,10
Slide 15: EBITDA and Adjusted EBITDA Reconciliations
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, (In thousands) 2024 2023 Net loss $ (110,228) $ (74,151) Interest expense (income) (1) 7,943 (4,107) Depreciation and amortization 53,943
Slide 16: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended March 31, (In thousands) 2024 2023 Net cash used in operating activities (82,311) (38,215) Net cash provi